Leucine Enkephalin (Leu-Enkephalin)

Overview

Leu-enkephalin (leucine enkephalin) is one of the two primary endogenous enkephalins identified by Hughes and Kosterlitz at the University of Aberdeen in 1975 — a landmark discovery that established the existence of endogenous opioid peptides and explained why opiate drugs produce their effects by mimicking natural brain signals.

The two enkephalins — met-enkephalin (YGGFM) and leu-enkephalin (YGGFL) — differ only at the fifth amino acid position (methionine vs. leucine). Both are derived from the precursor protein preproenkephalin (PENK) by proteolytic cleavage, are stored in synaptic vesicles in the CNS and spinal cord, and are released under conditions of pain and stress.

Mechanism

Opioid Receptor Selectivity

Leu-enkephalin's receptor preference:

| Receptor | Affinity | Notes | |----------|----------|-------| | δ-opioid (DOR) | High (primary) | Analgesia, mood, GI motility | | μ-opioid (MOR) | Moderate | Analgesia, reward, respiratory | | κ-opioid (KOR) | Low | Sedation, dysphoria |

The high DOR:MOR selectivity ratio (approximately 10:1) distinguishes enkephalins from morphine/opiates, which strongly prefer MOR. This selectivity profile means enkephalins produce analgesia and mood effects with a different pharmacological fingerprint than classical opiates.

Downstream Signaling

At δ-opioid receptors (Gαi/o-coupled):

1. Inhibits adenylyl cyclase → reduced cAMP → downstream protein kinase A inhibition
2. Activates inwardly rectifying K+ channels (GIRK) → neuronal hyperpolarization
3. Inhibits voltage-gated Ca²⁺ channels → reduced neurotransmitter release
4. Net effect: decreased excitatory neurotransmission at DOR-expressing synapses

GABA Modulation

DOR activation on GABAergic interneurons reduces inhibitory tone in specific circuits:

• Disinhibition of dopamine neurons in VTA → enhanced reward signaling
• Modulation of hippocampal interneurons → memory processing effects

Stability Challenge: Enkephalinase

The primary pharmacological limitation of leu-enkephalin for research is its extreme vulnerability to enkephalinase (neprilysin, NEP, CD10):

1. NEP cleaves the Gly-Phe bond (between positions 3 and 4) in seconds to minutes
2. Additional cleavage by aminopeptidase N at the N-terminal Tyr-Gly bond
3. Half-life: <2 minutes IV; ~15–30 minutes intranasal (slower mucosal metabolism)

Research strategies to address this:

• NEP inhibitors (thiorphan, racecadotril): Combined with enkephalins to extend activity
• Stable analogues (DADLE, DPDPE): Synthetic enkephalin analogues with modified Phe or Tyr residues resistant to degradation
• Intranasal delivery: Slower metabolic environment provides more research-practical delivery window

Research Context and Importance

Leu-enkephalin is primarily a mechanistic reference compound in opioid receptor pharmacology rather than a practical research tool. Its importance is foundational: without characterizing enkephalins, the opioid receptor subtypes would not have been defined, and the entire field of endogenous opioid biology would lack its molecular anchor.

Compounds that indirectly boost endogenous enkephalin levels — by inhibiting their degradation — are under active research as alternatives to direct opioid agonists for pain and mood disorders. Selank's mechanism, interestingly, includes partial enkephalinase inhibition.